Skip to main content

Advertisement

Table 1 Demographic and medical data of the sample

From: Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients

  Breast cancer patients (N = 92) Prostate cancer patients (N = 46)
Treatment group (N = 68) Control group
(N = 24)
p Treatment group (N = 25) Control group
(N = 21)
p
Patient demographics
 Age (years)
  Mean (SD) 54.3 (10) 52.5 (6.8) .535 64.11 (5.8) 65.7 (4.4) .330
  Range 29–72 39–65 47–73 58–75
 Cultural origin, N (%)
  Occidental Europe 66 (97.0) 0 NAa 25 (100) 21 (100) NAa
  Near and Middle East 1 (1.5) 0 0 0
  African 1 (1.5) 0 0 0
  Missing data 0 24 (100) 0 0
 Marital status, N (%)
  Single 5 (7.4) 1 (4.1) .778 1 (4.0) 0 .544
  Married/living with partner 52 (76.5) 18 (75) 20 (80.0) 16 (76.2)
  Divorced/separated/widowed 11 (16.2) 5 (20.8) 4 (16.0) 5 (23.8)
  Missing data 0 0 0 0
 Education level, N (%)
  Elementary school or less 0 3 (12.5) .001 1 (4.00) 2 (9.5) .557
  Lower secondary school 8 (11.8) 7 (29.2) 1 (4.00) 4 (19.0)
  Upper secondary school 21 (30.9) 8 (33.3) 7 (28.00) 5 (23.8)
  Bachelor’s degree 6 (8.8) 4 (16.7) 3 (12.00) 1 (4.8)
  Master’s degree 29 (42.6) 2 (8.3) 12 (48.00) 8 (38.1)
  Post-graduate 4 (5.9) 0 1 (4.00) 1 (4.8)
  Missing data 0 0   0 0  
 Employment status, N (%)
  Employed part or full time 9 (13.2) 8 (33.3) .080 8 (32.00) 4 (19.0) .344
  Employed, taken time off 38 (55.9) 12 (50) 2 (8.00) 3 (14.3)
  Not employed 20 (29.4) 4 (16.7) 15 (60.00) 14 (66.7)
  Missing data 1 (1.5) 0 0 0
Patient medical history
 Time since diagnosis (months)
  Mean (SD) 7.1 (5.1) 5.8 (5.0) .368 6.16 (3.52) 6.00 (4.3) .894
  Range 1–27 0.5–19 1–15 2–22
 Cancer stage, N (%)
  0 1 (1.5) 3 (12.5)   0 0  
  1 37 (54.4) 13 (54.2)   0 0  
  2 22 (32.4) 3 (12.5) .022 0 0  
  3 5 (7.4) 0   0 0  
  Missing data 3 (4.4) 5 (20.8)   25b 21b  
 Surgery, N (%)
  Yes 68 (100) 23 (95.8) NAa 25 (100) 21 (100) NAa
  No 0 0 0 0
  Missing data 0 1 (4.2) 0 0
 Chemotherapy (CT), N (%)
  CT completed 27 (39.7) 7 (29.2) .727 0 0 NAa
  During CT 20 (29.4) 8 (33.3) 0 0
  No CT 21 (30.9) 8 (33.3) 25 (100) 21 (100)
  Missing data 0 1 (4.2) 0 0
 Radiation therapy (RT), N (%)
  RT completed 30 (44.1) 6 (25) .280 1 (4.0) 0 .354
  During RT 6 (8.8) 2 (8.3) 0 0
  Not yet started 16 (23.5) 10 (41.7) 0 0
  No RT 16 (23.5) 5 (20.8) 24 (96.0) 21 (100)
  Missing data 0 1 (4.2) 0 0
 Hormonal therapy (HT), N (%)
  During HT 38 (55.9) 8 (33.3) .209 2 (8.0) 1 (4.8) .658
  Not yet started 23 (33.8) 11 (45.8) 0 0
  No HT 7 (10.3) 4 (16.7) 23 (92.0) 20 (95.2)
  Missing data 0 1 (4.2) 0 0
  1. Bold values indicate significant difference (p < .05)
  2. aNA (Not applicable) when missing data impeded the analysis, or when the two groups are exactly equivalent (p = 1)
  3. bAll prostate cancer patients were recruited after their surgery and none had metastases